Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Praxis Precision Medicines (PRAX) EBITDA Margin (2023 - 2024)

Praxis Precision Medicines has reported EBITDA Margin over the past 2 years, most recently at 856.97% for Q4 2024.

  • Quarterly results put EBITDA Margin at 856.97% for Q4 2024, up 454225.0% from a year ago — trailing twelve months through Sep 2025 was 3927.51% (up 629149.0% YoY), and the annual figure for FY2024 was 2340.29%, up 282412.0%.
  • EBITDA Margin for Q4 2024 was 856.97% at Praxis Precision Medicines, up from 18819.54% in the prior quarter.
  • Over the last five years, EBITDA Margin for PRAX hit a ceiling of 856.97% in Q4 2024 and a floor of 18819.54% in Q3 2024.